Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023.
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
Shares of Wells Fargo rose 3.9% after the San Francisco bank’s fourth-quarter profit of $1.43 a share beat expectations of $1 ...
Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback